EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma

Diogo Garcia, Isa Mambetsariev, Jeremy Fricke, Daniel Schmolze, Michelle Afkhami, Rifat Mannan, Pauline Kim, Shaira Therese Dingal, Bao Nguyen, Razmig Babikian, Yuman Fong, Ravi Salgia

Molecular Case Studies · 2023

DOI: 10.1101/mcs.a006262 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, 2023. Verfasst von Diogo Garcia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, City of Hope, Duarte, California 91010, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma of Lung, Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A small percentage of patients have multiple synchronous primary cancers at presentation. In the last five years, many regimens associated with immunotherapy and chemotherapy were approved for first-line metastatic non-small-cell lung cancer (NSCLC) and other solid tumors, but the study of immunotherapy when multiple cancers are present in one patient remains incomplete. Next-generation sequencing biomarkers and immunotherapy markers including PD-L1 can be effectively utilized in the diagnosis and treatment plan for multiple synchronous primary cancers. Immune biomarkers and PD-L1 expression warrant individualized treatments in synchronous primary adenocarcinoma and pulmonary sarcomatoid carcinoma. We describe the case of a patient with pulmonary sarcomatoid carcinoma and lung adenocarcinoma, metastatic to brain de novo. The patient achieved a complete response after only three cycles of carboplatin, paclitaxel, bevacizumab, and atezolizumab and remains free of any evidence of disease after 18 mo of maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinoma of LungCarcinomaNeoplasms, Multiple PrimaryHumansBevacizumabB7-H1 AntigenImmunotherapy

Stichwörter der Autor:innen

lung adenocarcinomaneoplasm of the lung

Substanzen

BevacizumabB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, City of Hope, Duarte, California 91010, USA.
  • Department of Pathology, City of Hope, Duarte, California 91010, USA.
  • Department of Ambulatory Pharmacy, City of Hope, Duarte, California 91010, USA.
  • Department of Diagnostic Radiology, City of Hope, Duarte, California 91010, USA.
  • Department of Surgery, City of Hope, Duarte, California 91010, USA.
  • Department of Medical Oncology, City of Hope, Duarte, California 91010, USA; rsalgia@coh.org.

Förderung

  • NCI NIH HHS

Zitieren

APA

Garcia, D., Mambetsariev, I., Fricke, J., Schmolze, D., Afkhami, M., Mannan, R., Kim, P., Therese Dingal, S., Nguyen, B., Babikian, R., Fong, Y., & Salgia, R. (2023). Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Molecular Case Studies. https://doi.org/10.1101/mcs.a006262

Vancouver

Garcia D, Mambetsariev I, Fricke J, Schmolze D, Afkhami M, Mannan R, et al. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Molecular Case Studies. 2023. doi:10.1101/mcs.a006262

BibTeX
@article{Garcia2023,
  author = {Garcia, Diogo and Mambetsariev, Isa and Fricke, Jeremy and Schmolze, Daniel and Afkhami, Michelle and Mannan, Rifat and Kim, Pauline and Therese Dingal, Shaira and Nguyen, Bao and Babikian, Razmig and Fong, Yuman and Salgia, Ravi},
  title = {Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma},
  journal = {Molecular Case Studies},
  year = {2023},
  doi = {10.1101/mcs.a006262}
}
Kostenlos starten →